KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Payables (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Payables for 16 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Payables fell 27.83% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, down 27.83% year-over-year, with the annual reading at $5.5 million for FY2025, 27.83% down from the prior year.
  • Payables hit $5.5 million in Q4 2025 for Arbutus Biopharma, up from $4.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.0 million in Q4 2022 to a low of $4.5 million in Q2 2025.
  • Historically, Payables has averaged $9.2 million across 5 years, with a median of $9.2 million in 2023.
  • Biggest five-year swings in Payables: soared 70.07% in 2021 and later tumbled 59.42% in 2025.
  • Year by year, Payables stood at $10.8 million in 2021, then skyrocketed by 47.9% to $16.0 million in 2022, then tumbled by 35.92% to $10.3 million in 2023, then dropped by 26.36% to $7.6 million in 2024, then dropped by 27.83% to $5.5 million in 2025.
  • Business Quant data shows Payables for ABUS at $5.5 million in Q4 2025, $4.7 million in Q3 2025, and $4.5 million in Q2 2025.